How AI Agents Reduce Time-to-Therapy for Specialty Medications

The average time-to-therapy for specialty medications is 29 days from referral to paid fill. That is nearly a month of administrative processing before a patient receives a drug their physician already prescribed. For complex therapies, the wait stretches past 45 days.

During that wait, patients fall through the cracks. Across 85 specialty brands studied by BrightInsight and Claritas Rx, only 62% of specialty prescriptions ever reach a paid fill. Nearly four in ten never do. When out-of-pocket costs exceed $500, abandonment climbs above 60% (IQVIA).

The financial stakes are enormous. Specialty medications represent just 2-3% of U.S. prescription volume but account for 53% of net drug spending, more than $260 billion annually (IQVIA, 2024). With nearly 40% of those prescriptions going unfilled, the revenue at risk across the specialty drug ecosystem spans hundreds of billions of dollars.

The bottleneck is not clinical. It is administrative. Between the moment a physician writes a specialty prescription and the moment a patient receives their first dose, five sequential stages of paperwork, phone calls, and portal navigation must complete. Each stage depends on the one before it. A single delay compounds across the entire pipeline.

This guide maps those five stages, quantifies where time is lost at each step, and shows how AI agents are compressing the specialty access pipeline from weeks to days.

Where Are Days Lost in the Specialty Medication Journey?

Time-to-therapy for specialty medications is the total number of days from prescription to first dose, typically spanning 10 to 28 days across five administrative stages.

The journey begins when a provider writes a prescription for a specialty drug and ends when the patient receives their first fill. Between those two events, five sequential steps must clear before the medication ships.

Note: Individual stage timelines are industry estimates consistent with published data from the CAQH Index, AMA Prior Authorization Survey, and specialty pharmacy literature. The 29-day average referral-to-paid-fill from BrightInsight/Claritas Rx falls within this range.

Benefit Verification

The first step confirms what the patient's insurance covers for the specific drug prescribed. For specialty medications, this goes well beyond a standard eligibility check.

Standard EDI 270/271 electronic transactions return basic coverage status. They miss therapy-specific details: specialty benefit carve-outs, step therapy requirements, preferred pharmacy networks, and whether prior authorization is required for the specific drug. Staff must call payers directly or navigate payer portals to extract this information.

The CAQH 2024 Index reports that manual eligibility checks average 12.64 minutes each. But specialty drugs often involve both medical and pharmacy benefits, with coverage split across multiple benefit layers. A single verification can require several calls to confirm which benefit applies, what the formulary tier is, and whether any utilization management criteria exist.

Prior Authorization

Prior authorization is the longest single bottleneck in the specialty access pipeline. The 2024 AMA Prior Authorization Survey found that 93% of physicians report PA causes delays in patient care.

For electronic prior authorization (ePA), Surescripts reports a median payer decision time of 5.7 hours. But that figure reflects only the payer's decision window once they receive the request. The full cycle for specialty drugs includes gathering clinical documentation (chart notes, lab results, prior therapy history), submitting through payer-specific channels, and responding to requests for additional information.

When the initial request is denied, the appeals process adds days or weeks. For specialty drugs requiring complex clinical justification, the total PA cycle commonly stretches to 5-14 days.

Financial Assistance

Once coverage terms are known and authorization is secured, many specialty patients face out-of-pocket costs that threaten fill completion. Financial assistance enrollment connects patients with copay cards, manufacturer patient assistance programs (PAPs), and independent foundation grants.

The manual process requires a counselor to identify available programs, verify patient eligibility against each program's criteria (diagnosis, insurance type, income thresholds), complete separate application forms, and submit supporting documentation. For patients qualifying for multiple programs, this creates days of sequential research and paperwork.

Specialty Pharmacy Transfer

The prescription must route to a specialty pharmacy equipped to handle the specific drug. This involves coordination between the prescriber, the patient's insurance plan (which may mandate a preferred specialty pharmacy), and the receiving pharmacy.

Transfer delays arise from incomplete referrals, missing clinical information, and insurance-mandated network restrictions. When a prescription must redirect from one specialty pharmacy to another because of payer requirements, the rerouting process can add days.

Patient Onboarding

Before receiving their first dose, patients need education about their medication (administration, side effects, storage requirements), must complete consent documentation, and often need to schedule an infusion appointment or injection training session.

Reaching the patient is itself a bottleneck. Staff make repeated calls, leave voicemails, and wait for callbacks. Multi-touch outreach across different times of day can take several days before the patient is fully onboarded and ready for their first dose.

The Compounding Effect

These five stages are sequential. Benefit verification must complete before PA submission. PA must be approved before the pharmacy can dispense. Financial assistance often cannot finalize until coverage terms and PA status are confirmed.

A one-day delay in benefit verification does not add one day to total time-to-therapy. It pushes every downstream step back by at least that amount. This compounding effect explains why the average specialty medication takes 29 days from referral to fill despite no individual stage (except PA) exceeding a few days on its own.

What Does Delayed Therapy Actually Cost?

Delayed access to specialty medications produces clinical harm, financial waste, patient disengagement, and lost manufacturer revenue that compounds across every day of waiting.

Clinical Impact

For time-sensitive conditions, delays are measured in outcomes, not just days. In oncology, weeks of treatment delay correlate with disease progression and reduced survival. A 2020 study published in The BMJ found that a four-week treatment delay increased mortality risk across surgery, systemic therapy, and radiotherapy for seven cancer types.

For autoimmune conditions like rheumatoid arthritis, delayed treatment allows irreversible joint damage during the window when disease-modifying therapies would be most effective. Early intervention with biologics can prevent structural damage, but that window narrows with every week of administrative delay.

In rare diseases, patients may have no therapeutic alternatives. Gene therapies, enzyme replacements, and orphan drugs often represent the only available treatment. For these patients, time-to-therapy is not a convenience metric. It is the difference between managed disease and progressive decline.

The BrightInsight/Claritas Rx data underscores this disparity. Life-threatening drugs in their dataset achieved paid fills 27% faster than non-life-threatening drugs, suggesting that urgency does accelerate the process. But even life-threatening medications still faced significant access delays, and non-life-threatening specialty drugs (which include many autoimmune and chronic condition therapies) had some brands with fill rates below 40%.

Financial Impact

Delayed therapy generates downstream healthcare costs that far exceed the administrative expenses of the access process itself. Patients who abandon specialty prescriptions due to access barriers often present later in emergency departments or require more intensive interventions.

The administrative costs alone are significant. Reprocessing a denied claim costs approximately $118 per occurrence (Becker's Hospital Review, 2017 data). Scale this across the thousands of specialty PAs a health system or hub program processes annually, and denied-claim rework becomes a multi-million dollar line item. But the clinical costs of delayed treatment (hospitalizations, disease progression, escalated care) are orders of magnitude higher.

Patient Impact

Patients waiting weeks for specialty medication access experience anxiety about their condition, confusion about the administrative process, and frustration with a system they cannot navigate independently. Extended waits erode trust in both the prescribing provider and the healthcare system.

The data confirms this pattern. The 38% non-fill rate from BrightInsight/Claritas Rx reflects not only financial barriers but also process fatigue. Patients who do not understand why their medication is delayed, or who cannot reach someone to explain the next step, often stop pursuing the prescription entirely.

Manufacturer Impact

For pharmaceutical manufacturers, unfilled specialty prescriptions represent direct revenue loss at the highest-value end of their portfolio. With specialty drugs totaling more than $260 billion in annual net U.S. spending (IQVIA, 2024), the non-fill gap of nearly 40% puts tens of billions of dollars in direct revenue at risk, with downstream healthcare costs multiplying the total.

Beyond top-line revenue, unfilled prescriptions weaken real-world outcomes data, reduce the adherence metrics that payers use for coverage decisions, and undermine the clinical evidence needed for formulary placement and contract negotiations. Every abandoned prescription is both lost revenue and a lost data point.

How Do AI Agents Address Each Bottleneck?

AI agents automate each stage of the specialty access pipeline by engaging directly with payers, portals, and patients, compressing timelines from days to hours.

The core difference between AI automation and earlier approaches (EDI transactions, basic portal scripting, offshore staffing) is scope. Traditional tools address individual transactions within a single stage. AI agents handle entire workflows across stages, adapting to exceptions rather than failing when they encounter them.

Benefit Verification

AI workers contact payers by phone, navigate IVR systems, and extract therapy-specific coverage details that standard electronic transactions miss. They simultaneously access payer portals to pull benefit information, capturing the full picture in a single interaction: specialty carve-out status, step therapy sequences, PA requirements, preferred pharmacy networks, and accumulator/maximizer program details.

This matters because a standard EDI eligibility check might return "active coverage" while missing that the drug requires prior authorization, is carved out to a separate pharmacy benefit manager, or has step therapy requirements the patient has already satisfied under a previous plan.

At Neon Health, AI workers process benefit verifications in real time rather than in daily batches, reducing this step from days to hours. When the BV reveals PA is required, the system immediately routes to authorization rather than waiting for a human to review the results and initiate the next step.

Prior Authorization

AI agents compile clinical documentation from available sources (EHR data, lab results, prior therapy records), submit PA requests through payer-specific channels, monitor request status, and respond to payer questions for additional information.

The most impactful capability is pre-submission intelligence. AI systems assess whether a PA request is likely to be approved based on the clinical evidence available, the payer's documented criteria, and historical approval patterns for that drug and payer combination. Straightforward cases route to automated submission. Complex cases that need physician narrative or supplemental clinical justification are flagged for human review with the relevant documentation pre-assembled.

For initial denials, AI handles appeal preparation: identifying the specific denial reason, gathering the clinical evidence needed to address it, and submitting the appeal within payer-mandated timelines. This matters because missed appeal deadlines result in permanent denials that restart the entire process.

Result: the 5-14 day manual PA cycle compresses to hours for straightforward cases and 1-2 days for complex appeals.

Financial Assistance Enrollment

AI agents match patients to eligible copay cards, manufacturer PAPs, and foundation grants based on diagnosis, insurance status, and financial criteria. They screen eligibility across multiple programs simultaneously, complete application forms, and handle digital income verification.

Manual financial assistance enrollment requires counselors to research available programs, verify eligibility one program at a time, and complete separate applications for each. A patient might qualify for a manufacturer copay card, a foundation grant, and a state assistance program, but discovering and enrolling in all three manually takes days of sequential work.

AI compresses this into a single parallel process: identifying every program the patient qualifies for, ranking them by coverage value, and enrolling in the optimal combination. Same-day enrollment replaces days of counselor research.

Patient Onboarding and Coordination

AI systems handle patient outreach across multiple channels (text, phone, email), educate patients about their medication, collect missing information from patients and providers, verify remaining insurance details, and schedule first-dose appointments or training sessions.

Traditional onboarding requires staff to make repeated phone calls, leave voicemails, and wait for callbacks across business hours. AI agents initiate outreach immediately and engage patients through their preferred channel at any hour. When a patient responds to a text at 9 PM, the AI processes their response and moves to the next onboarding step instantly, rather than waiting for next-business-day staff follow-up.

Onboarding that takes 1-3 days manually drops to 24 hours.

Real-World Results: From Days to Hours

Published case studies show that AI-driven automation is producing measurable time-to-therapy improvements across different approaches, organizations, and therapy areas.

AssistRx CoAssist

AssistRx's digital intake platform CoAssist reduced average time-to-therapy from 12.2 days to 3.7 days, a 70% reduction. The system achieved half of PA decisions within one hour and 70% within the same day. Patient outreach turnaround dropped from 19 minutes of staff time to 12 seconds via automated text (Drug Channels, March 2024, authored by Adam Stotts, SVP at AssistRx).

The compression happened across multiple intake stages simultaneously, not from optimizing a single step.

House Rx

House Rx reports a 3.5-day average fill time for specialty medications on its AI-enabled pharmacy management platform, compared to the 15.5-day industry standard. Their system generates prior authorization requests in 15 seconds and submits them in under 60 seconds, achieving a 92% first-pass approval rate (House Rx, PRNewswire, April 2025).

That 92% first-pass approval rate matters. Each avoided denial eliminates the appeal process (days to weeks of additional delay) and the roughly $118 administrative cost of reworking the claim.

Surescripts Touchless Prior Authorization

Surescripts' Touchless PA achieves fully automated approval in 22-27 seconds when the prescriber's clinical documentation meets the payer's criteria (Surescripts). No human on either side reviews the request.

In a pilot with Cleveland Clinic and Optum Rx, Touchless PA reduced turnaround from 8.5 hours to under 30 seconds. This applies specifically to cases where clinical criteria are clearly met and both prescriber and payer support the touchless workflow. Complex cases requiring clinical judgment still need human review.

Neon Health

Neon Health takes a different approach from point solutions. Rather than automating a single step, the platform deploys AI workers across the entire access pipeline: benefit verification, prior authorization, financial assistance enrollment, patient onboarding, and adherence support.

These AI workers engage directly with payers, portals, and patients, operating like trained staff that handle the complete workflow rather than isolated transactions. Because all five stages run as a coordinated pipeline, the compounding effect of sequential delays is resolved at the system level.

The result: patients reach therapy twice as fast at 80% lower operational cost (Neon Health, self-reported).

The Common Thread

These implementations share a pattern. The largest time savings come not from making individual tasks faster but from eliminating the manual handoffs between stages. When AI handles benefit verification and immediately routes the result into PA submission, the gap between those two stages drops from days to seconds. When PA approval triggers automatic financial assistance screening and patient outreach in parallel, days of sequential work collapse into hours.

The shift is architectural, not incremental. Traditional optimization speeds up each step. AI automation removes the seams between them.

How Do You Measure Time-to-Therapy Improvement?

Measuring time-to-therapy improvement requires tracking each access stage independently, establishing baselines segmented by therapy area, and benchmarking against the 29-day industry average before implementing automation.

Stage-Level Metrics

Measure each stage of the access pipeline separately rather than only tracking end-to-end time:

• Rx to BV completion: days from prescription to completed benefit verification

• BV to PA submission: days from verified benefits to prior authorization request

• PA submission to decision: days from submission to payer approval or denial

• Decision to first fill: days from approval to patient receiving medication

• End-to-end TTT: total days from prescription to first dose

Tracking stages independently reveals which bottlenecks are driving total time-to-therapy. A team that automates PA but leaves BV untouched may see minimal improvement if BV delays are pushing PA submission back by three days.

Establishing Baselines

Pull data from the last 90 to 180 days of specialty prescriptions. Segment by therapy area, because oncology, autoimmune, and rare disease access timelines differ significantly. The BrightInsight/Claritas Rx data confirms this: life-threatening drugs filled 27% faster than non-life-threatening drugs across their 85-brand dataset.

Report both median and 75th percentile values, not just averages. Averages are skewed by outlier cases (complex appeals, rare payer edge cases) that obscure the typical patient's experience. The median tells you what most patients encounter. The 75th percentile shows how bad the tail gets.

For cross-industry benchmarking, the 29-day average referral-to-paid-fill from BrightInsight/Claritas Rx provides a useful reference point.

ROI Framework

Calculate the cost of your current process at each stage: staff time per case, phone and fax expenses, rework from errors, and appeal costs for denied claims. Then add the revenue impact of abandoned prescriptions.

For every percentage point improvement in fill rate, calculate the revenue recovery based on your product's average annual cost of therapy. A drug with a $100,000 annual cost and 1,000 annual prescriptions at a 62% fill rate generates $62 million in revenue. Moving to a 72% fill rate adds $10 million.

Combine operational savings (lower cost-per-patient) with revenue recovery (higher fill rates) to build the full ROI case. The operational savings alone are often compelling, but the revenue recovery from reduced abandonment is typically the larger number for manufacturer-sponsored hub programs.

Consider the full picture: a hub program processing 5,000 specialty prescriptions annually with $80 in staff cost per case spends $400,000 on access workflows. An 80% cost reduction saves $320,000 in direct operational costs. But if the same program improves its fill rate from 62% to 72% on a $50,000 annual therapy, the revenue recovery is $25 million. The revenue impact dwarfs the operational savings.

This is why time-to-therapy improvement should be framed as a revenue initiative, not just an efficiency project. The teams that secure budget and executive support for AI automation are the ones presenting fill-rate improvement alongside cost-per-case reduction.

What Comes Next

Time-to-therapy is the metric that connects administrative efficiency to patient outcomes. Every day removed from the access pipeline is a day a patient starts treatment sooner, a day of disease progression prevented, and revenue recovered from what would have been an abandoned prescription.

The five-stage specialty access pipeline creates compounding delays when handled manually. AI agents address this not by speeding up individual tasks but by eliminating the handoffs between them. The published case studies in this guide show 70% or greater reductions in total access time.

The data is clear on where to focus. Prior authorization is the longest single bottleneck, but it is not the only one worth automating. Financial assistance enrollment, benefit verification, and patient onboarding each contribute days that compound across the pipeline. Organizations that address all five stages see the largest improvements because they eliminate the compounding effect, not just the individual delays.

The organizations setting the standard for specialty medication access are the ones treating time-to-therapy as a system-level metric rather than a collection of independent bottlenecks. They are measuring each stage, automating the handoffs between them, and tracking fill rates as a revenue outcome.

Neon Health's AI workforce automates the full access pipeline from benefit verification through patient onboarding, getting patients on therapy faster while cutting operational costs. Learn how Neon Health can reduce your time-to-therapy.

Frequently Asked Questions

What is time-to-therapy for specialty medications?

Time-to-therapy is the number of days from when a specialty medication is prescribed to when the patient receives their first dose. The industry average is 29 days from referral to paid fill, according to BrightInsight and Claritas Rx data across 85 specialty brands. Complex therapies involving multiple prior authorization steps or restricted distribution networks can take 45 days or longer.

Why are specialty prescriptions abandoned?

Specialty prescriptions are abandoned due to high out-of-pocket costs, lengthy prior authorization processes, complex enrollment requirements, and poor communication during the waiting period. Abandonment exceeds 60% when patients face more than $500 in out-of-pocket costs. Process fatigue from extended, unexplained waits also drives patients to stop pursuing their prescriptions entirely.

How long does prior authorization take for specialty drugs?

Prior authorization for specialty drugs typically takes 5 to 14 days when handled manually, including documentation gathering, payer review, and potential appeals. Electronic prior authorization (ePA) achieves a median payer decision time of 5.7 hours according to Surescripts, but the full cycle including clinical documentation and follow-up requests extends well beyond that window.

Can AI fully automate prior authorization for specialty medications?

AI can fully automate straightforward prior authorizations where clinical criteria are clearly met. Surescripts Touchless PA achieves approval in 22 to 27 seconds for qualifying requests with zero human intervention. Complex cases that require clinical narrative or supplemental justification still need human review, but AI handles documentation compilation, submission, status tracking, and appeal preparation.

What is the ROI of reducing time-to-therapy?

ROI comes from multiple sources: lower prescription abandonment, reduced staff costs per patient, fewer denied claims and appeals, decreased emergency utilization from delayed treatment, and higher medication adherence rates. For a $100,000 annual therapy, moving from a 62% to a 72% fill rate on 1,000 prescriptions recovers $10 million in annual revenue. Published case studies show 70% or greater reductions in time-to-therapy alongside 80% operational cost savings.

Key Takeaways

• The average specialty medication takes 29 days from referral to paid fill, with nearly 40% of prescriptions never reaching a paid fill across 85 studied brands.

• Specialty drugs account for 53% of net U.S. drug spending (more than $260 billion annually), and the revenue at risk from unfilled prescriptions reaches hundreds of billions across the ecosystem.

• Five sequential administrative stages (benefit verification, prior authorization, financial assistance, pharmacy transfer, patient onboarding) create compounding delays where one bottleneck pushes every downstream step back.

• AI agents compress each stage by engaging directly with payers, portals, and patients, eliminating the manual handoffs between steps rather than just making individual tasks faster.

• Published case studies show 70% or greater reductions in time-to-therapy, with prior authorization alone dropping from days to seconds in qualifying cases.

• Measuring improvement requires stage-by-stage tracking with baselines segmented by therapy area, using medians and 75th percentiles rather than averages.

• The largest gains come from treating time-to-therapy as a system-level problem, automating the full access pipeline rather than optimizing individual bottlenecks.

Sources

• BrightInsight and Claritas Rx. "Abandonment and Discontinuation Variation in Specialty Drugs." Accessed February 2026.

• IQVIA Institute. "Medicine Use and Spending in the U.S.: A Review of 2018 and Outlook to 2023." 2020.

• IQVIA Institute. "The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028." 2024.

• CAQH. "2024 CAQH Index." 2024.

• American Medical Association. "2024 AMA Prior Authorization Survey." 2024.

• Surescripts. "Electronic Prior Authorization." Accessed February 2026.

• Surescripts. "Touchless Prior Authorization Surpasses 76,000 Prescribers." Press release. Accessed February 2026.

• House Rx. "House Rx Announces First AI-Enabled Pharmacy Management Platform." PRNewswire, April 2025.

• Drug Channels. Adam Stotts (SVP, AssistRx). "Three Digital Intake Strategies for Specialty Pharma." March 2024. Note: sponsored content.

• The BMJ. Hanna et al. "Mortality Due to Cancer Treatment Delay: Systematic Review and Meta-Analysis." 2020.

• Becker's Hospital Review. "The Cost of a Denied Claim." 2017 data.

• Neon Health. Company website. Self-reported metrics. Accessed February 2026.